Search results for "MESH: Neoplasm Staging"

showing 4 items of 4 documents

Factors Associated With Fatigue After Surgery in Women With Early-Stage Invasive Breast Cancer

2013

Abstract Learning Objectives Describe the effect of worsening fatigue after breast cancer surgery on physical functioning and psychological distress. Better identify women at risk for developing cancer-related fatigue. Direct target interventions to patients most in need. Purpose. Fatigue is one of the most frequent symptoms in patients with cancer. However, the precise determinants of fatigue are still unknown. This study was conducted to investigate factors correlated with cancer-related fatigue before surgery and just before subsequent adjuvant therapy. Methods. Patients completed the Multidimensional Fatigue Inventory (MFI-20), the European Organization for Research and Treatment of Can…

MESH: FatigueCancer ResearchMultivariate analysisMESH: Lymph NodesDisease0302 clinical medicineMESH: Aged 80 and overQuality of lifeSurveys and Questionnaires030212 general & internal medicineNeoplasm Metastasisskin and connective tissue diseasesFatigueAged 80 and overMESH: AgedMESH: Middle AgedMESH: Neoplasm StagingMiddle Aged3. Good healthOncologySymptom Management and Supportive Care030220 oncology & carcinogenesisAnxietyMarital statusFemalemedicine.symptomAdultmedicine.medical_specialtyBreast Neoplasms03 medical and health sciencesBreast cancerAdjuvant therapymedicineHumansNeoplasm InvasivenessMESH: Surveys and QuestionnairesAgedNeoplasm StagingMESH: Humansbusiness.industryCancerMESH: Quality of LifeMESH: AdultMESH: Neoplasm Invasivenessmedicine.diseaseMESH: Neoplasm MetastasisSurgeryQuality of Life[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieLymph NodesbusinessMESH: FemaleMESH: Breast Neoplasms
researchProduct

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with adv…

2012

Purpose The combination of pertuzumab and trastuzumab resulted in a clinical benefit rate (CBR) of 50% in patients with human epidermal growth factor receptor 2 (HER2) –positive breast cancer whose disease progressed during prior trastuzumab-based therapy. To define whether this previously observed encouraging activity was a result of the combination of pertuzumab and trastuzumab or of pertuzumab alone, we recruited a third cohort of patients who received pertuzumab without trastuzumab. We then investigated the impact of reintroducing trastuzumab to patients whose disease progressed on pertuzumab monotherapy. Patients and Methods Twenty-nine patients with HER2-positive breast cancer whose d…

OncologyCancer ResearchReceptor ErbB-2MESH: Risk AssessmentMESH: Dose-Response Relationship Drug0302 clinical medicineTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsMedicineProspective StudiesProspective cohort studyskin and connective tissue diseasespertuzumab; trastuzumab; breast cancerMESH: Treatment OutcomeMESH: Aged0303 health sciencesMESH: Middle AgedMESH: ErythrocytesAge FactorsMESH: Maximum Tolerated DoseMESH: Neoplasm StagingMiddle AgedPrognosis3. Good healthtrastuzumabMESH: Antineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeOncologyTolerabilityMESH: Receptor erbB-2030220 oncology & carcinogenesisMESH: Survival AnalysisDisease Progression[SDV.IMM]Life Sciences [q-bio]/ImmunologyMESH: Disease ProgressionFemalePertuzumabmedicine.drugAdultmedicine.medical_specialty[SDV.IMM] Life Sciences [q-bio]/ImmunologyMaximum Tolerated DoseMESH: Blood TransfusionBreast NeoplasmsMESH: Drug Administration ScheduleAntibodies Monoclonal HumanizedLoading doseMESH: Cell SeparationRisk AssessmentMESH: PrognosisDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesbreast cancerBreast cancerMESH: PrionspertuzumabInternal medicineHumansMESH: Patient SelectionNeoplasm InvasivenessneoplasmsSurvival analysis030304 developmental biologyAgedNeoplasm StagingMESH: Age FactorsMESH: HumansDose-Response Relationship Drugbusiness.industryPatient SelectionMESH: AdultMESH: Neoplasm InvasivenessMESH: Creutzfeldt-Jakob SyndromeTrastuzumabmedicine.diseaseSurvival AnalysisMESH: Prospective StudiesMESH: Antibodies Monoclonal HumanizedMESH: Disease-Free SurvivalbusinessMESH: FemaleProgressive diseaseMESH: Breast NeoplasmsJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consens…

2008

Objectives: The first consensus report presented by the European Germ Cell Cancer Consensus Group (EGCCCG) in the year 2004 has found widespread approval by many colleagues throughout the world. In November 2006, the group met a second time under the auspices of the Department of Urology of the Amsterdam Medical Center, Amsterdam, The Netherlands. Methods: Medical oncologists, urological surgeons, radiation oncologists as well as pathologists from several European countries reviewed and discussed the data that had emerged since the 2002 conference, and incorporated the new data into updated and revised guidelines. As for the first meeting, the methodology of evidence-based medicine (EBM) wa…

MaleMESH: Combined Modality TherapyBiopsyConsensus Development Conferences as Topic030232 urology & nephrologyMembrane transport and intracellular motility [NCMLS 5]MESH: Biopsy0302 clinical medicineStage I SeminomaMESH: Practice Guidelines as TopicMedicineSocieties MedicalMESH: Testicular NeoplasmsConsensus conferenceMESH: Neoplasm StagingNeoplasms Germ Cell and EmbryonalPrognosisPrimary tumorCombined Modality Therapy3. Good healthEurope030220 oncology & carcinogenesisPractice Guidelines as TopicMESH: Neoplasms Germ Cell and Embryonalmedicine.medical_specialty[SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT]ConsensusUrologyMESH: Societies MedicalMEDLINEMESH: Prognosis03 medical and health sciencesSDG 3 - Good Health and Well-beingTesticular NeoplasmsInterventional oncology [UMCN 1.5]HumansMESH: ConsensusTesticular cancerNeoplasm StagingGynecologyMESH: Humansbusiness.industryMESH: Consensus Development Conferences as Topicmedicine.diseaseMESH: MaleClinical trialGerm cell cancerFamily medicineGerm cell tumorsMESH: EuropebusinessEuropean Urology
researchProduct

Influence of sample return time and ambient temperature on the performance of an immunochemical faecal occult blood test with a new buffer for colore…

2016

IF 2.415; International audience; The haemoglobin concentration measured by faecal immunochemical tests (FIT) may be decreased in cases of delayed sample return or high temperature. It is an issue of great importance. The aim of this study was to investigate the effects of sample return time and of season on the performance of an FIT (FOB-Gold) with a new buffer. The study included 20 371 participants involved in the French organized colorectal cancer (CRC) screening programme. The probability of a positive screening test, detection rates and positive predictive values for CRC and advanced adenoma were analysed according to sample return time and season of screening. A sample of positive FI…

MaleCancer ResearchMultivariate analysisTime FactorsEpidemiologyColorectal cancerMESH: Reagent Kits DiagnosticMESH : AgedMESH : HemoglobinsMESH : Early Detection of Cancer[ SDV.CAN ] Life Sciences [q-bio]/CancerReturn timeScreening programmeImmunoenzyme TechniquesHemoglobinsMESH : Specimen HandlingMESH : FemaleMESH : Neoplasm StagingMESH : Reagent Kits DiagnosticMESH : TemperatureEarly Detection of CancerMESH: AgedMESH: Middle AgedMESH : PrognosisTemperatureMESH: Follow-Up StudiesMESH: Neoplasm StagingMiddle AgedPrognosisPredictive valueMESH: TemperatureMESH: HemoglobinsMESH : Occult BloodOncologyColorectal cancer screeningOccult BloodFemaleSeasonsMESH : Colorectal NeoplasmsColorectal NeoplasmsMESH : Time FactorsAdenomamedicine.medical_specialtySample (material)MESH : Male[SDV.CAN]Life Sciences [q-bio]/CancerMESH: PrognosisSpecimen HandlingAnimal scienceMESH : Immunoenzyme TechniquesmedicineHumansMESH: Early Detection of CancerMESH : Middle AgedMESH: Specimen HandlingMESH: Immunoenzyme TechniquesAgedNeoplasm StagingMESH: AdenomaMESH: HumansMESH : Seasonsbusiness.industryMESH: Time FactorsMESH : HumansPublic Health Environmental and Occupational HealthMESH : Follow-Up Studiesmedicine.diseaseMESH: MaleSurgeryMESH : AdenomaReagent Kits DiagnosticFaecal occult blood testbusinessMESH: Occult BloodMESH: FemaleMESH: SeasonsMESH: Colorectal NeoplasmsFollow-Up Studies
researchProduct